Shots:

• Agios to receive ~$1.8B upfront in cash & ~$200M as regulatory milestones for Vorasidenib along with 5% royalties on sales of Tibsovo in the US from transaction close through the loss of exclusivity and 15% royalties on sales of vorasidenib in the US from first commercial sale through the loss of exclusivity
• The acquisition is expected to close in Q2’21. The acquisition allows Servier to strengthen its product portfolio and drug development pipeline in oncology
• The transaction includes the transfer of Agios' oncology portfolio and associated employees- including its Tibsovo and pipeline and clinical programs- including vorasidenib

 ­ Ref: PRNewswire  | Image: Enzo Life Sciences